<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269061</url>
  </required_header>
  <id_info>
    <org_study_id>ADG104148</org_study_id>
    <nct_id>NCT00269061</nct_id>
  </id_info>
  <brief_title>Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin</brief_title>
  <official_title>An Exploratory MRI Study in Type 2 Diabetic Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Measurement of Fluid Volumes by MRI in the Lower Extremities of Subjects Receiving Pioglitazone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will use Magnetic Resonance Imaging (MRI) techniques to evaluate changes in fluid&#xD;
      volume in the lower legs of diabetic patients who add either pioglitazone or placebo to their&#xD;
      current diabetic regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in interstitial fluid volume in the lower extremities as measured by MRI.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessments of other indicators of fluid volume changes, including labwork evaluation, fluid compartment volume measurement, direct measurement of the calf.</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Non-Insulin-Dependent Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Must have been diagnosed with Type 2 diabetes at least three months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Must be taking either metformin and a sulfonylurea, metformin and insulin, or insulin&#xD;
             only, and doses of these medications must have been stable for at least three months.&#xD;
&#xD;
          -  Must have a Body Mass Index (BMI) of between 24 and 35.&#xD;
&#xD;
          -  If female, the subject must be post-menopausal.&#xD;
&#xD;
          -  HbA1c levels must be between 7% and 10%.&#xD;
&#xD;
          -  Subjects must be eligible for MRI scanning (ie, no metal implants, pacemaker, etc).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Suffer from claustrophobia.&#xD;
&#xD;
          -  Use of tobacco, nicotine, or illegal drugs of abuse.&#xD;
&#xD;
          -  Use of caffeine within two days prior to each study visit.&#xD;
&#xD;
          -  HIV, hepatitis, edema, untreated blood pressure problems, heart, lung, nervous system&#xD;
             or kidney disease, history of blood clots in the legs, diabetic neuropathy, or&#xD;
             untreated thyroid disease.&#xD;
&#xD;
          -  Use of drugs or medications that affect the levels of fluid in the body, such as&#xD;
             diuretics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2005</study_first_posted>
  <last_update_submitted>October 15, 2008</last_update_submitted>
  <last_update_submitted_qc>October 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>pioglitazone</keyword>
  <keyword>diabetes</keyword>
  <keyword>fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

